Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

BACKGROUND: We tried to investigate the prognostic significance of post-treatment eosinophil percentage(Eo %) in metastatic renal cell carcinoma(mRCC) patients undertaking sorafenib. RESULTS: The median OS for the entire sorafenib treatment period was 21.9 months (95% CI: 17.2–25.9 months). Of the 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hong-Kai, Wan, Fang-Nin, Gu, Wei-Jie, Zhu, Yao, Dai, Bo, Shi, Guo-Hai, Zhang, Hai-Liang, Ye, Ding-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356602/
https://www.ncbi.nlm.nih.gov/pubmed/27661105
http://dx.doi.org/10.18632/oncotarget.12126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356602/
https://www.ncbi.nlm.nih.gov/pubmed/27661105
http://dx.doi.org/10.18632/oncotarget.12126

Ejemplares similares